Abstract
Introduction: Cognitive tests and nonamyloid imaging biomarkers do not consistently identify preclinical AD. The objective of this study was to evaluate whether white matter hyperintensity (WMH) volume, a cerebrovascular disease marker, is more associated with preclinical AD than conventional AD biomarkers and cognitive tests. Methods: Elderly controls enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 158) underwent florbetapir-PET scans, psychometric testing, neuroimaging with MRI and PET, and APOE genetic testing. Elderly controls the Parkinson's progression markers initiative (PPMI, n = 58) had WMH volume, cerebrospinal fluid (CSF) Aβ1-42, and APOE status measured. Results: In the ADNI cohort, only WMH volume and APOE ε4 status were associated with cerebral Aβ (standardized β = 0.44 and 1.25, P = .03 and .002). The association between WMH volume and APOE ε4 status with cerebral Aβ (standardized β = 1.12 and 0.26, P = .048 and .045) was confirmed in the PPMI cohort. Discussion: WMH volume is more highly associated with preclinical AD than other AD biomarkers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 18-27 |
| Number of pages | 10 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 4 |
| DOIs | |
| State | Published - 2016 |
Keywords
- Aging
- Alzheimer's disease
- Amyloid
- Leukoaraiosis
- MRI
- PET
- Preclinical Alzheimer's disease
- White matter
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health